CSIMarket


Cryoport inc   (CYRX)
Other Ticker:  
 


 

Cryoport inc

CYRX's Financial Statements and Analysis



Cryoport inc increased forth quarter of 2023 net loss per share of $-1.30 compare to net loss per share of $-0.22 recorded in the same quarter a year ago a decrease compare to $-0.31 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -1.3 $  57 Mill
$-1.08     $-3M     -5.13 %



Cryoport Inc 's Revenue fell by -5.13 % in forth quarter of 2023 (Dec 31 2023) year on year, to $57 million and advanced by 1.96 % sequentially.


Cryoport Inc is

More on CYRX's Income Statement



Cryoport Inc 's in theforth quarter of 2023 recorded net loss of $-64.389 million, an increase from net loss of $-11.436 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on CYRX's Growth

Cryoport Inc Inventories
Inventories declined by -5.32 % to $26.21 million from IV. Quarter a year ago, sequentially inventories fell by -9.96 %. In Dec 31 2023 company's net cash and cash equivalents decreased by $-13 million, capital expenditures fell by -8.46444.64%, to $-12 millions compare to same quarter a year ago

More on CYRX's Cash flow Statement


Cryoport inc does not pay out common stock dividend.

In trailing twelve-month period Cryoport inc payed $ -0.02 cash per share, on a free-cash flow basis .

Book value fell by -8.61 % sequentially to $10.05 per share, -43.12% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value grew to $ 3.83 per share from $ 3.50.

Company repurchased 0.22 million shares or 0.45 % in Dec 31 2023.


More on CYRX's Dividends

 Market Capitalization (Millions) 739
 Shares Outstanding (Millions) 49
 Total Debt (Millions $) 380
 Revenue (TTM) (Millions $) 233
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) -45
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 31




Cryoport inc does not pay out common stock dividend.

In trailing twelve-month period Cryoport inc had negative $ -0.02 cash flow per share, on a free-cash flow basis .

Book value fell by -8.61 % sequentially to $10.05 per share, -43.12% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value grew to $ 3.83 per share from $ 3.50.

Company repurchased 0.22 million shares or 0.45 % in Dec 31 2023.


More on CYRX's Balance Sheets

 Market Capitalization (Millions) 739
 Shares Outstanding (Millions) 49
 Total Debt (Millions $) 380
 Revenue (TTM) (Millions $) 233
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) -45
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 31
   


  News about Cryoport inc Earnings

Cryoport Inc Faces Challenges as Deficit Per Share Surges in Q4 2023

Cry...

Cryoport Inc's latest fiscal period sees staggering losses surpassing previous year's figures at Major Pharma Preparations firm



Cryoport Inc, a leading provider of cold chain logistics solutions, has seen its stock gain 16.5% over the last five trading days, demonstrating some positive momentum. However, while this may seem promising, it is important to examine the recent financial results to understand the potential implications for the company's future.
1. Declining Revenue and Widening Losses:
In the most recent fiscal period, Cryoport Inc experienced a decline in revenue to $56.16 million, a decrease of 7.123% compared to the previous year. This decrease can be attributed to lower demand, which has resulted in fading revenue. Furthermore, the company's net loss for the period amounted to $-15.269 million, surpas...

Cryoport Inc Reports Substantial Losses on Weak Sales Throughout Fiscal Second Quarter of 2023


Date: [Today's Date]
Cryoport Inc, a leading provider of critical temperature logistics solutions for the life sciences industry, has reported disappointing financial results for the second quarter of 2023. The company's loss per share increased to $-0.42 compared to $-0.23 a year ago, representing a significant surge from the previous financial reporting period's loss of $-0.16 per share.
Revenue for the April to June 30, 2023 span declined considerably by -11.117% to $57.02 million from $64.15 million in the corresponding financial reporting period a year ago. Sequentially, revenue deteriorated by -9.227% from $62.82 million. This decline is in stark contrast to the on-average Major Pharmaceut...

Cryoport Inc Shows Promising Top-Line Growth in Q1 2023, but Sustainability Remains a Concern

Cryoport Inc seems to be on the rise based on their first quarter of 2023 results with a decrease in loss per share and an inc...


Date modified: 2024-03-13T23:04:03+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com